ARID1A and non-small cell lung carcinoma: ARID1A mutations were present in 6–11.3% of non-small-cell lung carcinomas (NSCLC), of which the majority (44–69%) were loss of function mutations [117,118,119,120], while less than 2% showed diffuse loss of expression [118,121].